OSAKA, Japan, August 29, 2025

日本大阪，2025年8月29日

- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter, 'Shionogi') today announced that its project, aimed at promoting the appropriate use of Japan-origin antimicrobials and hygiene products through digital transformation (DX) in healthcare facilities in the Republic of Kenya (“Kenya”), has been selected for the FY2024 Supplementary Budget Grant Program for Future-Oriented Co-Creation with the Global South (Small-Scale Demonstration and Feasibility Study Projects) administered by the Ministry of Economy, Trade and Industry (METI)..

盐野义制药株式会社（总公司：日本大阪；首席执行官：手代木功博士；以下简称“盐野义”）今日宣布，其旨在通过数字转型（DX）促进肯尼亚共和国（“肯尼亚”）医疗机构适当使用日本来源的抗菌药物和卫生产品的项目，已被经济产业省（METI）管理的2024财年补充预算资助计划“面向未来的与全球南方共创合作（小规模示范与可行性研究项目）”选中。

Under this project, Shionogi will collaborate with Saraya Co., Ltd. (“Saraya”) to examine the feasibility of implementing digital tools to support antimicrobial stewardship and strengthen infection control systems in Kenyan healthcare settings, where antimicrobial resistance (AMR) poses a critical public health challenge.

在此项目下，盐野义制药将与 Saraya Co., Ltd.（“Saraya”）合作，研究在肯尼亚医疗环境中实施数字工具以支持抗菌药物管理和加强感染控制系统的可行性，因为在这些地区，抗菌药物耐药性 (AMR) 构成了严峻的公共卫生挑战。

By leveraging digital solutions to efficiently monitor and visualize antimicrobial usage and infection control practices, the Project seeks to contribute to the promotion of appropriate antimicrobial use..

通过利用数字解决方案有效监控和可视化抗菌药物使用及感染控制措施，该项目旨在促进抗菌药物的合理使用。

In Kenya, more than 28,000 deaths in 2021 were attributed to infections caused by AMR pathogens

在肯尼亚，2021 年有超过 28,000 例死亡归因于由 AMR 病原体引起的感染。

1

1

. Establishing a robust framework for appropriate antimicrobial use is therefore an urgent societal priority. Through this Project, Shionogi aims to facilitate optimal antimicrobial selection for patients with infectious diseases, and enhance infection control practices in Kenyan hospitals. Looking ahead, the initiative also seeks to expand its impact to other African countries, thereby contributing to the prevention of AMR emergence and spread across the region..

因此，建立一个强大的适当使用抗菌药物的框架是当前社会的迫切优先事项。通过该项目，盐野义制药旨在帮助感染病患者选择最佳的抗菌药物，并提升肯尼亚医院的感染控制实践。展望未来，该倡议还寻求将其影响扩大到其他非洲国家，从而为预防该地区抗菌药物耐药性（AMR）的出现和传播做出贡献。

Shionogi has identified “Improve Access to Healthcare” as one of its material issues, and continues to strengthen collaborative initiatives with domestic and international partners.² In line with this commitment, Shionogi is actively working to improve access to AMR treatments* and supporting maternal and child health programs in Africa**.

盐野义制药已将“改善医疗保健的可及性”确定为其重要议题之一，并持续加强与国内外合作伙伴的协作。² 在此承诺下，盐野义制药正积极努力改善抗微生物药物耐药性（AMR）治疗的可及性*，并支持非洲地区的母婴健康项目**。

As a leading company in infectious disease care, Shionogi remains dedicated to addressing major public health threats, such as AMR and COVID-19, through sustained innovation and partnerships..

作为传染病护理领域的领先公司，Shionogi 致力于通过持续的创新和合作应对主要的公共卫生威胁，如抗微生物药物耐药性和 2019 冠状病毒病。

*For more information on Shionogi’s initiatives on AMR, please click [

*如需了解更多关于Shionogi在AMR领域的举措，请点击[

here

这里

].

].

**For more information on Shionogi’s maternal and child health initiatives in Africa, please click [

**如需了解更多关于盐野义在非洲的母婴健康计划的信息，请点击[

here

这里

].

].

About Saraya Co., Ltd.

关于萨拉亚有限公司

Saraya is committed to creating a prosperous and sustainable global society under the three core pillars of “Hygiene,” “Environment,” and “Health.” Since its founding in 1952, Saraya has developed and delivered a wide range of products and services, from detergents and disinfectants to health foods, serving both professional and household markets.

沙拉雅致力于在“卫生”、“环境”和“健康”三大核心支柱下创建一个繁荣且可持续的全球社会。自1952年成立以来，沙拉雅已经开发并提供了一系列广泛的产品和服务，从洗涤剂、消毒剂到健康食品，服务于专业市场和家庭市场。

In Africa, Saraya began local production and sales of alcohol-based hand disinfectants in Uganda in 2014, and has since expanded its product supply to Kenya, South Sudan, and the Democratic Republic of the Congo. Through collaborations with the Japan International Cooperation Agency (JICA) and local ministries of health, Saraya also contributes to training healthcare professionals in infection control practices..

2014年，萨拉亚在乌干达开始本地生产和销售酒精类手部消毒剂，并逐步将产品供应扩展到肯尼亚、南苏丹和刚果民主共和国。通过与日本国际协力机构（JICA）以及当地卫生部门的合作，萨拉亚还为培训医疗卫生专业人士的感染控制实践作出贡献。

https://www.saraya.com/

https://www.saraya.com/

About Antimicrobial Resistance

关于抗菌素耐药性

Antimicrobial resistance (AMR), the phenomenon where bacteria acquire resistance to antibiotics, is one of the most significant global public health threats facing humanity and requires urgent action. AMR has been referred to as a 'silent pandemic”, and without countermeasures, it is projected to result in over 10 million deaths annually by 2050.

抗菌素耐药性 (AMR) 是指细菌对抗生素产生耐药性的现象，是人类面临的最严重的全球公共卫生威胁之一，需要采取紧急行动。AMR 被称为“无声的大流行病”，如果不采取应对措施，预计到 2050 年每年将导致超过 1000 万人死亡。

3,4

3，4

Reference:

参考：

1.     Institute for Health Metrics and Evaluation (IHME). (2022). MICROBE: Measuring Infectious Causes and Resistance Outcomes for Burden Estimation. VizHub.

1.     健康指标与评估研究所 (IHME)。 (2022)。 MICROBE：衡量传染病原因及抗药性结果以估算负担。 VizHub。

https://vizhub.healthdata.org/microbe

https://vizhub.healthdata.org/microbe

2.     Press release on May 9, 2025

2.     2025年5月9日的新闻稿

Shionogi, Nagasaki University, Saraya, and Connect Afya Enter into a Comprehensive Partnership Agreement to Support Antimicrobial Stewardship in Kenya

盐野义制药、长崎大学、Saraya和Connect Afya签署全面合作协议，支持肯尼亚的抗菌药物管理。

3.

3.

Global antimicrobial resistance forum launched to help tackle common threat to planetary health

全球抗菌素耐药性论坛启动，以帮助应对对行星健康的共同威胁

4.     O’Neill J. ‘Tackling Drug-Resistant Infections Globally: Final Report and Recommendations’. Review on Antimicrobial Resistance. May 2016. Retrieved from

4.     奥尼尔 J. 《全球应对耐药性感染：最终报告与建议》。抗菌素耐药性评估。2016年5月。检索自

https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf

https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf

Forward-Looking Statements

前瞻性声明

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate.

本公告包含前瞻性陈述。这些陈述是基于目前可获得的信息和预期，这些假设受风险和不确定性的影响，可能导致实际结果与这些陈述有重大差异。风险和不确定性包括一般国内和国际经济状况，如一般行业和市场状况，以及利率和汇率的变化。

These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations.

这些风险和不确定性尤其适用于与产品相关的前瞻性声明。产品风险和不确定性包括但不限于：临床试验的完成和中止；获得监管批准；对产品安全性和有效性的主张和担忧；技术进步；重要诉讼的不利结果；国内外医疗改革以及法律法规的变更。

Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise..

对于现有产品，也存在生产和营销风险，包括但不限于无法建立满足需求的生产能力、原材料供应不足以及竞争产品的进入。公司否认有任何意图或义务更新或修改任何前瞻性声明，无论是否由于新信息、未来事件或其他原因。

For Further Information, Contact:

如需更多信息，请联系：

SHIONOGI Website Inquiry Form :

SHIONOGI网站咨询表：

https://www.shionogi.com/global/en/contact.html

https://www.shionogi.com/global/zh/contact.html